With this ground-breaking invention, the Vericheck ddPCR Empty-Full Capsid Kit streamlines the AAV development to produce dependable results. Using ddPCR technology, obtaining absolute ...

The biotech is developing a Huntington’s disease (HD) gene therapy based on its proprietary capsid, AAV-DB-3. HD damages the neurons in the striatum, leading Latus to target the deep brain.

Figure 3. Cerebral organoids as models for (A) Parkinson’s disease and (B) AAV capsid screening. Image Credit: ACROBiosystems Human iPSC-derived cardiac organoids generated via Cardiac Organoid ...

With their increasing adoption, precise tools are vital for quantifying AAV capsid titers and detecting anti-AAV antibodies to ensure the safety, efficacy and proper dosing of therapies. This ...

In this interview, NewsMedical speaks to Dr Chelsea Pratt about Accurately quantifying AAV capsids directly from crude lysates with Bio-Rad's new ddPCR kit. The Vericheck ddPCR Empty-Full Capsid ...

One capsid, AAV-KP1, stood out as particularly effective when administered directly to the kidneys via the renal vein or pelvis, reaching kidney cells with minimal impact on the liver. In contrast ...

Sangamo Therapeutics Inc.’s second large, worldwide licensing deal for its capsid technology in the past five months is with Astellas Pharma Inc. The California-based company is getting $20 million up ...

Sandy Macrae, Chief Executive Officer, Sangamo "We strongly believe in the potential of STAC-BBB, our industry-leading, intravenously delivered AAV capsid, to overcome the challenges associated ...

(PRNewsFoto/Astellas Pharma Inc.) Sandy Macrae, Chief Executive Officer, Sangamo "We strongly believe in the potential of STAC-BBB, our industry-leading, intravenously delivered AAV capsid, to ...